Centessa Pharmaceuticals (CNTA) Research & Development (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Research & Development of $59.9 million for Q1 2026, up 79.08% year-over-year from $33.4 million in Q1 2025, and up 9.94% on a QoQ basis from $54.5 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 7 years of Research & Development data on file, last reported at $59.9 million in Q1 2026.
- Quarterly Research & Development rose 79.08% year-over-year to $59.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198.7 million (up 23.37% YoY) and the FY2025 annual result came in at $172.2 million, up 14.63% from the prior year.
- Research & Development improved to $59.9 million in Q1 2026 per CNTA's latest filing, from $54.5 million in the prior quarter.
- Across five years, Research & Development topped out at $60.9 million in Q4 2024 and bottomed at $22.7 million in Q1 2024.
- The 5-year median for Research & Development is $33.9 million (2024), against an average of $38.9 million.
- The widest annual swing landed in 2022, when Research & Development soared 263.37%; it then sank 37.24% in 2023.
- Tracing CNTA's Research & Development over 5 years: stood at $27.8 million in 2022, then rose by 6.76% to $29.7 million in 2023, then soared by 104.85% to $60.9 million in 2024, then slipped by 10.51% to $54.5 million in 2025, then climbed by 9.94% to $59.9 million in 2026.
- Per Business Quant, the three latest CNTA Research & Development figures stand at $59.9 million (Q1 2026), $54.5 million (Q4 2025), and $41.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | 59.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.89 Mn |
| Dec 31, 2025 | 54.48 Mn |
| Sep 30, 2025 | 41.56 Mn |
| Jun 30, 2025 | 42.74 Mn |
| Mar 31, 2025 | 33.44 Mn |
| Dec 31, 2024 | 60.87 Mn |
| Sep 30, 2024 | 33.90 Mn |
| Jun 30, 2024 | 32.82 Mn |
| Mar 31, 2024 | 22.65 Mn |
| Dec 31, 2023 | 29.72 Mn |
| Sep 30, 2023 | 28.19 Mn |
| Jun 30, 2023 | 33.67 Mn |
| Mar 31, 2023 | 32.83 Mn |
| Dec 31, 2022 | 27.84 Mn |
| Sep 30, 2022 | 36.74 Mn |
| Jun 30, 2022 | 53.65 Mn |
| Mar 31, 2022 | 36.85 Mn |
| Dec 31, 2021 | 41.53 Mn |
| Sep 30, 2021 | 25.85 Mn |
| Jun 30, 2021 | 18.13 Mn |
| Mar 31, 2021 | 10.14 Mn |
| Dec 31, 2020 | 2.70 Mn |
| Sep 30, 2020 | 1.92 Mn |
| Jun 30, 2020 | 1.87 Mn |